ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project

Autor: Shustov, A., Cabrera, M. E., Civallero, M., Bellei, M., Y. H., Ko, Manni, M., Skrypets, T., Horwitz, S. M., de Souza, C. A., Radford, J. A., Bobillo, S., Prates, M. V., Ferreri, A. J. M., Chiattone, C., Spina, M., Vose, J. M., Chiappella, A., Laszlo, D., Marino, D., Stelitano, C., Federico, M., Savage, K., Connors, J., Gascoyne, R., Chhanabhai, M., Wilson, W., Jaffe, E. S., Armitage, J. O., Weisenburger, D. D., Anderson, J., Ullrich, F., Bast, M., Hochberg, E., Harris, N., Smogorzews ka, A., Levine, A., Nathwani, B. N., Miller, T., Rimsza, L., Montserrat, E., Lopez-Guillermo, A., Campo, E., Cuadros, M., Ferreira, J. A., Delgado, B. M., Holte, H., Delabie, J., Rudiger, T., Muller-Hermelink, K., Reimer, P., Adam, P., Wilhelm, M., Schmitz, N., Nerl, C., Lister, A., Norton, A., Maclennan, K. A., Zinzani, P. L., Pileri, S. A., Bellai, M., Luminari, S., Coiffier, B., Berger, F., Tanin, I., Wannakrairot, P., W. Y., Au, Liang, R., Loong, F., Rajan, S., Sng, I., Tobinai, K., Matsuno, Y., Morishima, Y., Nakamura, S., Seto, M., Tanimoto, M., Yoshino, T., Suzumiya, J., Ohshima, K., Kim, W. -S.

Publikováno v: Shustov, A, Cabrera, M E, Civallero, M, Hyeh Ko, Y, Manni, M, Skrypets, T, Horwitz, S M, de Souza, C A, Radford, J, Bobillo, S, Prates, M V, Ferreri, A J M, Spina, M, Vose, J M, Chiappella, A, Laszlo, D, Stelitano, C & Frederico, M 2021, ' ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project ', Blood Advances, vol. 5, no. 3, 3, pp. 640-648 . https://doi.org/10.1182/bloodadvances.2020001581
Blood Adv

Anaplastic lymphoma kinase–negative anaplastic large cell lymphoma (ALK– ALCL) is an aggressive neoplasm of T-cell/null-cell lineage. The T-Cell Project is a global prospective cohort study that consecutively enrolled patients newly diagnosed wit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77d8ff357df1d67aa6e5469dd7bc4930
https://doi.org/10.1182/bloodadvances.2020001581

Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin’s lymphoma

Autor: Tulpule, A. ^*, Rarick, M.U., Kolitz, J., Bernstein, J., Myers, A., Buchanan, L.A., Espina, B.M., Traynor, A., Letzer, J., Justice, G.R., McDonald, D., Roberts, L., Boswell, W., Nathwani, B., Levine, A.M.

Publikováno v: In Annals of Oncology April 2001 12(4):457-462

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-Cell Lymphoma Project

Autor: Suzumiya J, Ohshima K, Tamura K, Karube K, Uike N, Tobinai K, Gascoyne RD, Vose JM, Armitage JO, Weisenburger DD, for the International Peripheral T. Cell Lymphoma Project [Savage K, Connors J, Gascoyne R, Chhanabhai M, Wilson W, Jaffe E, Armitage J, Vose J, Weisenburger D, Anderson J, Ullrich F, Bast M, Hochberg E, Harris N, Levine A, Nathwani B, Miller T, Rimsza L, Montserrat E, Lopez Guillermo A, Campo E, Cuadros M, Alvarez Ferreira J, Martinez Delgado B, Holte H, Delabie J, Rüdiger T, Müller Hermelink K, Reimer P, Adam P, Wilhelm M, Schmitz N, Nerl C, MacLennan KA, Federico M, Bellei M, Coiffier B, Berger F, Tanin I, Wannakrairot P, Au W, Liang R, Loong F, Rajan S, Sng I, Matsuno Y, Morishima Y, Nakamura S, Seto M, Tanimoto M, Yoshino T, Kim WS, Ko Y.H. ], ZINZANI, PIER LUIGI, PILERI, STEFANO

Background: The International Peripheral T-cell Lymphoma Project was organized to better understand the T-cell and natural killer (NK) cell lymphomas, and our task is to present the clinicopathologic correlations and therapeutic results for adult T-c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44cefa6a20199fa7260dc1f3a34e0df7
http://hdl.handle.net/11585/119626

International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes

Autor: Savage K, Connors J, Gascoyne R, Chhanabhai M, Wilson W, Jaffe E, Armitage J, Vose J, Weisenburger D, Anderson J, Ullrich F, Bast M, Hochberg E, Harris N, Levine A, Nathwani B, Miller T, Rimsza L, Montserrat E, Lopez Guillermo A, Campo E, Cuadros M, Alvarez Ferreira J, Martinez Delgado B, Holte H, Delabie J, Rüdiger T, Müller Hermelink K, Reimer P, Adam P, Wilhelm M, Schmitz N, Nerl C, Lister A, Norton A, MacLennan KA, Federico M, Bellei M, Coiffier B, Berger F, Tanin I, Wannakrairot P, Au W, Liang R, Loong F, Rajan S, Sng I, Tobinai K, Matsuno Y, Morishima Y, Nakamura S, Seto M, Tanimoto M, Yoshino T, Suzumiya J, Ohshima K, Kim WS, Ko Y.H., ZINZANI, PIER LUIGI, PILERI, STEFANO

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(25)

Purpose Peripheral T-cell lymphoma (PTCL) and natural killer/T-cell lymphoma (NKTCL) are rare and heterogeneous forms of non-Hodgkin's lymphoma (NHL) that, in general, are associated with a poor clinical outcome. Patients and Methods A cohort of 1,31

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6fd31e2e0ab87c494b0c8f89f6be3e8
https://pubmed.ncbi.nlm.nih.gov/18626005